SCHEMBL10166483

SCHEMBL10166483

CN1CCc2nc3sc(C(=O)Nc4cccc(N)c4)c(N)c3cc2C1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 15/20 0.79
MPO P05164 1/20 0.79
ADORA2A P29274 1/20 0.75
TP53 P04637 5/20 0.71
ALDH1A1 P00352 4/20 0.69
KDM4E B2RXH2 3/20 0.69
KMT2A Q03164 3/20 0.69
MEN1 O00255 2/20 0.69
SMN1; SMN2 Q16637 2/20 0.68
NPSR1 Q6W5P4 2/20 0.67
CYP1A2 P05177 1/20 0.67
CYP2C19 P33261 1/20 0.67
POLB P06746 3/20 0.64
SHMT2 P34897 1/20 0.60
USP2 O75604 1/20 0.60
THRB P10828 1/20 0.60
ALOX15 P16050 1/20 0.60
CASP1 P29466 1/20 0.60
BRCA1 P38398 1/20 0.60
RECQL P46063 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL430097 0.92 ADORA2A (0.82) MAPTMPOADORA2ATP53ALDH1A1
SCHEMBL427153 0.91 ADORA2A (0.82) MAPTMPOADORA2ATP53ALDH1A1
SCHEMBL432028 0.89 MAPT (1.00) MAPTMPOADORA2ATP53ALDH1A1
SCHEMBL424745 0.89 TDP1 (0.74) MAPTMPOADORA2ATP53ALDH1A1
SCHEMBL425121 0.87 MAPT (0.71) MAPTMPOADORA2ATP53ALDH1A1
SCHEMBL428923 0.86 ADORA2A (0.80) MAPTMPOADORA2ATP53ALDH1A1
SCHEMBL430160 0.86 ADORA2A (1.00) MAPTMPOADORA2ATP53ALDH1A1
SCHEMBL430301 0.86 ADORA2A (0.83) MAPTMPOADORA2ATP53ALDH1A1
SCHEMBL425455 0.85 ADORA2A (0.82) MAPTMPOADORA2ATP53ALDH1A1
SCHEMBL430882 0.85 MAPT (1.00) MAPTMPOADORA2ATP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022046-A1 Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections SIGA TECHNOLOGIES, INC. 2012-01-26 US disclosed
WO-2010099166-A1 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS SIGA TECHNOLOGIES, INC. (US) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022046-A1 Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections TTPA, TPMT, SLC19A2 MAPT 138/4885MPO 2720/4885ADORA2A 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.